DDO and schizophrenia: The first study, performed on a small number of samples (7–10 subjects/diagnosis), revealed reduced d-Asp levels (about 40%) in the post-mortem PFC of schizophrenia-affected patients (101), linked to significantly increased DDO mRNA levels in the same brain area (94).